AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses
NCT04392206
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
15
Enrollment
OTHER
Sponsor class
Conditions
End Stage Renal Disease
Interventions
DRUG:
Adipose Derived Mesenchymal Stem Cells
Sponsor
Houssam Farres, M.D.